# Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

> **NCT00600886** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 358 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** Pasireotide
- **DRUG:** Octreotide

## Key facts

- **NCT ID:** NCT00600886
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02-11
- **Primary completion:** 2016-03-11
- **Final completion:** 2016-03-11
- **Target enrollment:** 358 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00600886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00600886, "Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00600886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*